Nuformix PLC
NFX
Company Profile
Business description
Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.
Contact
60 Gracechurch Street
6th Floor
LondonEC3V 0HR
GBRT: +44 1223627222
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
3
Stocks News & Analysis
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,136.60 | 15.10 | 0.17% |
| CAC 40 | 7,927.87 | 31.93 | 0.40% |
| DAX 40 | 23,984.72 | 104.00 | 0.44% |
| Dow JONES (US) | 46,397.89 | 81.82 | 0.18% |
| FTSE 100 | 9,413.43 | 63.00 | 0.67% |
| HKSE | 26,855.56 | 232.68 | 0.87% |
| NASDAQ | 22,660.01 | 68.86 | 0.30% |
| Nikkei 225 | 44,550.85 | 381.78 | -0.85% |
| NZX 50 Index | 13,433.99 | 141.63 | 1.07% |
| S&P 500 | 6,688.46 | 27.25 | 0.41% |
| S&P/ASX 200 | 8,845.70 | 12.30 | 0.14% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |